设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 763|回复: 0

CAR-T过继细胞治疗靶向治疗实体肿瘤的挑战

[复制链接]
发表于 2016-1-4 22:21:47 | 显示全部楼层 |阅读模式
Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.
Recent spectacular success in the adoptive cell therapy of leukemia and lymphoma with chimeric antigen receptor (CAR)-modified T cells raised the expectations that this therapy may be efficacious in a wide range of cancer entities. The expectations are based on the predefined specificity of CAR T cells by an antibody-derived binding domain that acts independently of the natural T-cell receptor, recognizes targets independently of presentation by the major histocompatibility complex and allows targeting toward virtually any cell surface antigen. We here discuss that targeting CAR T cells toward solid tumors faces certain circumstances critical for the therapeutic success. Targeting tumor stroma and taking advantage of TRUCK cells, in other words, CAR T cells with inducible release of a transgenic payload, are some strategies envisaged to overcome current limitations in the near future.
KEYWORDS:
CAR; T cell; adoptive cell therapy; cancer; chimeric antigen receptor; gene transfer
CAR-T过继细胞治疗靶向治疗实体肿瘤的挑战
近期过继CAR-T细胞治疗技术在白血病和淋巴细胞白血病的治疗中取得的成功,唤起了人们拓展这种技术可能在更多的实体肿瘤治疗中应用的期望。这种期望基于CAR-T的特异性,通过表达一种独立于天然T细胞的抗体衍生的结合域,它几乎能够针对细胞表面的任何抗原。这篇文章中,我们讨论了某些情况下,靶向CAR-T细胞治疗实体肿瘤成功的关键。靶向肿瘤的基质环境和利用TRUCK细胞,换句话说,使用转基因有效负荷的诱导释放,是不久的将来,克服目前局限性的一些战略设想。
关键词:
CAR; T cell; adoptive cell therapy; cancer; chimeric antigen receptor; gene transfer
CAR;细胞;细胞疗法;肿瘤;嵌合抗原受体;基因转移
出自爱康得生物技术

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-6-23 11:31 , Processed in 0.163419 second(s), 20 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表